Pfizer Halts Obesity Drug Development After Patient Liver Injury Concerns

Pfizer has stopped developing its experimental weight-loss pill due to a patient suffering liver injury during trials, marking a major setback for the company. The decision ends hopes for a new obesity treatment from the pharmaceutical giant. This news follows intense competition in the weight-loss drug market.

The drug, known as danuglipron, was in clinical trials when the liver injury occurred. Pfizer stated the patient’s condition resolved after stopping the medication.

Unlike rival drugs from companies like Eli Lilly, danuglipron aimed to offer a once-daily oral option. The company now plans to focus on earlier-stage obesity treatments.

Weight-loss drugs have gained attention as obesity rates rise, with over 40% of U.S. adults classified as obese. Pfizer’s exit leaves fewer players in a crowded but lucrative field.

The liver injury raised safety concerns, prompting Pfizer to halt further trials. Patient safety remains a top priority in drug development, the company noted.

The pharmaceutical industry has faced challenges balancing efficacy and side effects in weight-loss treatments. Past drugs, like fen-phen, were pulled due to severe health risks.

Some praise Pfizer for prioritizing patient safety over profit. Others criticize the company for abandoning a promising drug too soon.

Supporters argue halting development prevents potential harm from untested drugs. Critics say the decision limits options for those struggling with obesity.